The era of iPS? Advances of reverses infertility induced by chemotherapy or Premature Ovarian Failure

Stem cell breakthrough reverss infertility after cancer Scientists from Egypt's Mansoura Medical School show it is possible to restore fertility by injecting stem cells directly into the ovaries   By Sarah Knapton, Science Editor12:01AM BST 22 Oct 2015Cancer patients made infertile by chemotherapy have been offered new hope after scientists succeeded in reversing the damage caused to eggs for the first time. In a landmark breakthrough hailed as "phenomenal" by fertility experts, researchers from Egypt and the US showed that injecting stem cells into ovaries can bring them back to life. Chemotherapy is toxic to the ovaries, destroying eggs and ovarian tissue and triggering early menopause in some women. Many younger women are now advised to freeze their eggs before undergoing cancer treatment, but in urgent cases there is often not time. Now scientists have shown it is possible to restore fertility by injecting stem cells directly into the ovaries. "This is very exciting piece of research that adds to our understanding of how cells differentiate to become egg stem cells." Although the procedure has only been carried out in mice so far, the results were so successful that the researchers say they are ready to move to human trials. Mice who had suffered ovarian failure from chemotherapy were able to have large litters after treatment. The new treatment offers hope to more than 20,000 women of childbearing age who are diagnosed with cancer each year, and could also help those suffering from early menopause and ovarian failure. Lead researcher Dr Sara Mohamed, of Mansoura Medical School in Egypt, said she had come up with the idea after meeting a 22-year-old cancer patient who was at risk of infertility from chemotherapy. "It was a very emotional for me so I decided to pursue it and work on it to figure it out," she said. "It a very common problem based on statistics of cancer female diagnosis every year. "We inject stem cells in the ovaries of mice which had chemotherapy and were damaged and we got very good ovarian function restoration in form of follicle number, hormonal production and finally getting pregnant and having new pups which was our ultimate goal. "We are now working on translating that into clinical trials (for humans). This approach carries high promise to women with chemotherapy-induced and potentially other types of premature ovarian failure." In the trial involving 18 mice, one group were given chemotherapy and then ovarian injections of bone marrow stem cells, while another group had ovarian injections of saline. A third, control, group, had saline injections without the preceding chemotherapy. Within a week researchers saw a boost in oestrogen, an essential hormone in ovulation, in the stem cell group followed by regeneration in ovarian tissue after a fortnight and an increase in the number of follicles. Follicles produce the hormones oestrogen and progesterone and each carry a single egg which they release at ovulation. The mice who had suffered ovarian failure were able to go on to have large litters of pups while those who had saline injections struggled. Consultant Gynaecologist Dr Stuart Lavery, of Imperial College, said: "This is very exciting piece of research that adds to our understanding of how cells differentiate to become egg stem cells. "Clearly, there remains an enormous amount of work to see whether these results would be transferable into humans. "But it does provide some realistic hope that post-chemotherapy patients who have been made menopausal could one day restore ovarian function and possibly fertility." The researchers are now hoping to move to human trials using umbilical cord or even embryonic stem cells although they will still have to convince regulators the procedures are safe. Recent trials to stimulate stem cells in the ovaries were banned by the Food and Drug Agency (FDA). Currently women diagnosed with cancer can be be offered egg freezing, or even early stage IVF, before chemotherapy. But many trusts have cut IVF funding and women are sometimes denied cryopreservation. The new therapy would give peace of mind for women that something could be done to reverse the damage caused by chemotherapy. And because the new technique regenerates ovarian tissue the new eggs could be even healthier than they were before chemotherapy, experts have suggested. Women are born with all their eggs but they degrade over time. Stem cells have the potential to make eggs brand new again. Dr Geoffrey Trew, consultant in Reproductive Medicine and Surgery at Hammersmith Hospital, London, said: "Fertility-wise, if this works it would be stupendous. "Certainly it does appear promising and anything you can do to regenerate and ovary is a good thing. "Theoretically if you are regenerating the ovary you should be getting better quality eggs. "Clearly we're not here yet, and it's good that the researchers are not over-claiming their findings, but it's a great proof of concept." Dr Edgar Mocanu, consultant gynaecologist at Rotunda Hospital in Dublin and board member of the International Federation of Fertility Societies, said: "This could open phenomenal opportunities for women. "Millions of women around the world undergo cancer treatment and some of them will become infertile through ovarian failure. "While cancer survival rates have increased dramatically, to date there is no effective method of preventing infertility after chemotherapy. It could also open new avenues for the treatment of menopause induced health issues." "This approach carries high promise to women with chemotherapy-induced and potentially other types of premature ovarian failure." Lead researcher Dr Sara Mohamed Dr Owen Davis president of the American Society for Reproductive Medicine: "If this experimental treatment can be translated to women who have lost ovarian function from chemotherapy, it will be a great advance. "Restoring ovarian hormone production, follicle development and fertility to chemotherapy patients is a potential new application for bone marrow donation that could help many women." Coventry-based fertility expert Richard Kennedy, president-elect of the International Federation of Fertility Societies, said: "One of the really important messages for our cancer colleagues is that when men or women present for treatment, think about their fertility, think about the impact of the cancer treatment on their fertility.

Thousands of cancer patients to be denied treatment "That is a really important message because the majority of people with cancer now are living for five years or longer, and many are surviving their cancers, so thought about the long-term impact of treatment is important." Katherine Taylor, of Ovarian Cancer Action, said: "This sounds very promising and we welcome any new research that helps us build on our knowledge of cancer and fertility. We look forward to seeing how this research advances in years to come." The research was presented at the annual sheeting of then American Society for Reproductive Medicine in Baltimore.

Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure, ClinicalTrials.gov Identifier: NCT02043743, Sponsor:El-Rayadh Fertility Centre. Premature ovarian failure (POF), also known as premature ovarian insufficiency, primary ovarian insufficiency (this is the most accurate term as some women may still conceive), premature menopause, hypergonadotropic hypogonadism is defined as failure of the ovary to function adequately in a woman younger than 40 years, in its role either as an endocrine organ or as a reproductive organ, a condition characterized by amenorrhea, hypoestrogenism, and elevated serum gonadotropin levels (which demonstrate that the ovaries are no longer responding to circulating FSH by producing estrogen and developing fertile eggs) in women younger than 40 years. This condition occurs in approximately 1% of women and it has important physical and psychological consequences/impact in those patients. The purpose of this study is to investigate the role of the transplantation of bone marrow derived stem cells into ovarian tissue for treatment of premature ovarian failure and to assess their ability to differentiate into germ cells. This study is an open-label investigation of the efficacy of injection of autologous adult bone marrow derived stem cells into the ovarian stroma of patients with premature ovarian failure. Sixty women with premature ovarian failure will be recruited in this study after a written informed consent. Diagnosis will be based mainly on history taking, physical examination and investigations. Laboratory investigations will include Serum follicle-stimulating hormone (FSH), serum estrogen measurement and serum AMH. The anterior pituitary secretes FSH and LH at high levels due to the dysfunction of the ovaries and consequent low estrogen levels. Typical FSH in POF patients is over 40 mlU/ml (post-menopausal range). Subjects will be enrolled based on specific inclusion/exclusion criteria and evaluated at regular post transplant intervals. Human adult bone marrow derived stem cells will be transplanted by a gynecological surgeon through a standard surgical approach (transvaginal U/S guided approach). Subjects will be monitored frequently for a total of one year after adult bone marrow stem cells cell injection. For safety of participants, Bone Marrow Stem cells will be injected in one ovary only and the other ovary will be spared.

Ovarian cortex transplantation Time to move on from experimental studies to open clinical application, Posted by Thea Ryan on Wednesday, August 5, 2015 ,Authors:Jacques Donnez, M.D., Ph.D., Marie-Madeleine Dolmans, M.D., Ph.D., César Diaz, M.D., Ph.D., Antonio Pellicer, M.D., Ph.D.  Volume 104, Issue 5, Pages 1097-1098  Abstract: In the context of treating cancer, fertility preservation (FP) in young women is a major challenge. Many questions remain because controversial issues still exist (1). Unfortunately, only a small number of patients at risk of premature ovarian failure are referred to FP specialists to discuss different options. As reproduction specialists, we consider it vital to provide oncologists, hematologists, and all healthcare providers with accurate information, based on firm evidence, on fertility-sparing treatments, which could potentially have devastating consequences on their future quality of life.

Ovarian cortex transplantation in the baboon: comparison of four different intra-abdominal transplantation sites, Hum. Reprod. (2011) 26 (12): 3303-3311.BACKGROUND Several sites have been used for ovarian cortex transplantation (OCT) in humans. The present study was designed to evaluate different intra-abdominal transplantation sites in the baboon to gain further knowledge about alternative transplantation sites in a human setting.METHODS Autologous fresh OCTs were performed in 12 baboons (Papio anubis). Four different sites were tested: the free portion of the omentum (OMF), the portion of the omentum adjacent to the spleen (OMS), the pouch of Douglas (D) and the pelvic wall on the psoas muscle (PW). Cortex survival, follicle density, cyclicity and hormonal levels were compared between the different sites, 3 and 6 months after transplantation.RESULTS Macroscopically, antral follicles were only found in the OMS and OMF locations, which also showed a higher proportion of follicle-containing cortex at light microscopy (OMF 71.4%, OMS 83.3% versus PW 58.8% and D 40%, P< 0.05). Higher densities of primordial [OMF: 3.54 (0–13.18) follicles/grid, OMS: 3.85 (0–8.53), PW: 0 (0–13.25), D 0 (0–1.33), P< 0.05] and primary follicles [OMF: 3.54 (0–18.52), OMS: 3.85 (0–1), PW: 0 (0–4.58), D 0 (0–0.25), P< 0.05] was also found in the omental locations.CONCLUSIONS Omental locations provide a better site, in terms of follicle survival, for intra-abdominal OCT in the baboon compared with the pelvic wall and the D.

超級血型Cis-AB09 自己儲存血液自己用

B血型的父母生出AB血型的女兒，世界上首次發現"突變AB型"血型 OCTOBER 21, 2015 07:26 柳根亨記者 (noel@donga.com) 음성듣기父母都是B血型，但生出的子女卻是AB型。世界上首次發現"突變AB型(Cis-AB09)"血型。從遺傳學角度來看，通常父母都是B型的話，子女是B型或O型。三星首爾醫院教授趙德和順天鄉大學醫院教授申熙峰20日表示，在國際學術雜誌《輸血醫學》最新一期上刊登了上述內容的論文。趙教授指出，"在國際血庫上出現Cis-AB09血型尚屬首次。"首個被判定為Cis-AB09血型的人是一名29歲的女性，研究組在她為了卵巢囊腫手術而進行血液檢查的過程中發現了這一事實。 通常達到普通人的10 ~ 15%的普通AB型，大部分是從父母一方獲得A血型遺傳基因，從另一方獲得B血型遺傳基因。相反，能同時從父母中的任何一方繼承AB血型遺傳基因特性的AB型情況則被分類為Cis-AB血型，從Cis-AB01血型到Cis -AB08血型都有。此次發現的Cis-AB09血型，即使在Cis-AB血型中也是很罕見的情況。因為這是一種沒有從父母那裏得到遺傳基因的突變。趙教授解釋稱，"與引起遺傳基因突變的祖上一代不同的新的遺傳基因誕生。"像這種Cis-AB09血型無法從現有AB型身上接受輸血，只能從O型人身上接受輸血。研究組說，"碰到像這樣稀有血型的情況，平時最好儲存起自己的血液。"

Cis AB is a rare mutation in the ABO gene which complicates the basic inheritance pattern and blood-transfusion compatibility matching for ABO blood typing. There are different DNA mutations either type A or Type B alleles that change several amino acids in enzyme transferase A or B, homologous enzymes differing in only four of 354 amino acids (R176G, G235S, L266M, and G268A). A single change in ABO gene DNA could reverse type B to type A and then, a new hybrid enzyme B will produce a bit of A antigen (in serum test, A2B). The most common mutation is an A102 allele variation in exon 7 nucleotide position G803C changing Glycine (type A) to Alanine (type B). In the cis-AB genotype, both antigens are expressed, like in a standard (trans) AB genotype. In a traditional AB phenotype, A and B antigenes are inherited separately from the father and mother while a cis-AB allele comes from one parent only. In a serum test, cis-AB tests almost the same as a traditional AB, but people with this rare type have problems with blood transfusions. Some of them need components like washed red blood cells or autotransfusion of serum and blood. Cis-AB type was studied first in Japan (Shishoku Island) and South Korea (Gwanju area) where this rare type is more common (Chinese coast provinces and Taiwan, too), although it is also seen in a few European families (from France, Spain, Belgium, Germany, and Poland). In the year 2004, the American Red Cross described a family in Nebraska with a father of type cis-AB rh negative, a mother type O and their baby of type cis-AB. Since then, several cases in America have been reported. Antigen expression is weaker than A1 or B.

補充保費公平性之政治需求變形 ?!!

基因又突變的補充保費2015年10月21日00:12 作者：孫友聯／台灣勞工陣線秘書長補充保費又要基因突變了。衛福部長蔣丙煌宣佈，明年元旦起全面放寬利息、股利、租金及執行業務收入，單筆扣繳門檻一律由現行5千元放寬到2萬元。而按健保署估算，這次的調整將「惠及」約342萬人，平均可少繳784元，其中228萬人更是一毛不用繳，並宣稱是基於符合社會公平正義原則。打開電腦檔案夾中幾篇塵封已久的文章，反芻2011年1月4日立法院三讀通過健保法修法前後的記憶，在短短三天內「狸貓換太子」，原本規劃的「家戶總所得」硬被換成現行一般和補充保費併行的「變種異形」，也種下了日後基因突變、再變的禍根。回顧那次荒謬、滑稽的修法過程，從因應2010年調整費率至5.17%的政治壓力，馬政府昨非今是的把封殺多年的前朝版「二代健保」，原封不動的排入政治議程。而立法院衛環委員會經過無數委員會的逐條審查，保留了27條文交付政黨協商，但最終卻又峰迴路轉，在執政黨立委形同「倒閣」的徹底推翻已經一讀的行政院版，並強行表決通過財政委員會建議的現行版本。這兒戲般的修法不僅引發社會的嘩然，幾位前健保局總經理更聯名表達對二代健保蒙難的不滿和疑慮，而舊問題沒有解決，新問題接踵而至，也注定了補充保費未知的命運。官方宣稱，補充保費設計已達到擴大費基的社會公平性效果。但事實上，治絲益棼和價值錯亂的一般／補充保費設計，非但沒有解決原六類十四目被保險人保費負擔的結構性不公平問題，東扣西減、挑三揀四的費基擴大，以及不同身份類別被保險人和不同所得類別的補充保費義務不一，讓健保保費公平性問題更趨複雜，縱使原各界擔心收不到保費的疑慮沒有發生，如今反而因超收而有調整的空間，也無法掩蓋補充保費設計的公平性缺陷。補充保費上路以前，又在立法院的壓力之下又一再的限縮、調整，從各項原本擴大的所得範圍、不同身份的排除，以及保費收取的門檻等，行政機關不僅一再創下以子法扭曲母法的惡例，更隨心所欲的一再隨政治需求而變形，讓補充保費僅剩無幾的公平性蕩然無存。然而，既然目前健保財務無虞，衛福部該做的不是落井下石的傷害健保制度，而是提出更符合社會公平性的改革方案，讓已實施二十年的全民健保更能永續經營。最後，不僅還是要問，有誰關心失業勞工及其家屬每月要繳749元保費（約等於投保級距50,600元被保險人保費），這個根本性、結構性公平性的問題？

衛生署: 台灣亞洲第一胖 盛行率 38.3%，(男性45.9%/ 女性33.1%)!

基因、環境環環相扣　學者為肥胖一族提改善良方NOWnews今日新聞 2015年 10月 20日生活中心／綜合報導 財團法人人人體重管理基金會與中華民國營養師公會全國聯合會，共同在「台北醫學大學」首度舉辦台灣「基因、環境與肥胖國際學術研討會」，現場邀請包括亞太肥胖學會理事長Mohd Ismail Noor教授等國際著名肥胖醫學專家，針對最新的肥胖臨床研究報告與國內學者專家進行交流分享。 研討會中許多專家學者紛紛提出，雖然直接造成肥胖的主要原因為熱量的過多攝取，但許多環境與基因相關因素，包含遺傳、飲食習慣、社會環境等更是影響熱量攝取與吸收的本源。尤其，現代人超過8成有一至二餐靠外食解決，6成4的民眾因外食無法均衡營養，體內抗氧化維生素不足，再加上食物漸趨添加與精製，層出不窮的食安問題，更讓肥胖成因隨環境變遷而更加多元。 衛生署也疾聲呼籲，與日本、新加坡、馬拉西亞、南韓、泰國及中國等亞洲國家相比，台灣過重及肥胖盛行率高達38.3%，其中男性比率為45.9%、女性比例為33.1%，位居亞洲城市之冠，甚至因此獲得「亞洲第一胖」的稱號。而肥胖所帶來健康的威脅甚鉅，不僅是許多慢性病的主因，十大死因中更有癌症、腦中風、心臟病、高血壓、糖尿病、與慢性肝病等六項直接與肥胖有關。 肥胖衍生的醫療問題已經成為世界各國最重要的公共衛生課題之一，因此這次學術研討會由國內外專家學者，以基因、肥胖與環境相關議題演講，與最新進的臨床研究報告為主要成果發表，並透過國際交流，相互學習新知、交換經驗，提出有效的改善方法，達成體重管理目標、推動民眾參與。 其中亞太肥胖協會理事長Mohd Ismail Noor教授以「肥胖流行病之議題與挑戰」進行專題發表，而日本新陳代謝科大野 誠醫師，則以「節約基因與新陳代謝症候群」為題做專題演講、北京首都兒科研究所附屬兒童醫院米杰教授也以「兒童肥胖趨勢」發表專題，針對當前不分年齡與族群的肥胖問題進行討論及建議解套方案，格外具有意義。 而主辦方財團法人人人體重管理基金會董事長孫崇發表示，近年來科學家對於減重議題的研究已非放在節食策略的發展上，而是透過對遺傳學的了解，試圖尋找控制飲食和能量利用的基因、蛋白質和神經傳遞物質。有些人因先天性遺傳或後天如環境毒素、飲食不當等因素，使得基因弱化或某些生理功能下降，導致肥胖易成。 孫崇發博士指出，體內弱化的基因，多半都可藉由運動、飲食調理等方式加強，並透過專業的基因調理，輔以完美比例的均衡飲食、良好的生活習慣等，仍有機會恢復體內先天基因的相互協調性。孫崇發博士也建議，可以透過專業營養師等控重專家的評估與建議，培養正確觀念，從基因根本做起，從此遠離肥胖。

中國 腦卒中(中風)重災區: 發病年齡63歲(比美國早10年)

環球醫療構建卒中防治平台 共用高端學術盛宴 ACN (2015-10-20 19:37) 香港, 2015年10月20日 - (亞太商訊) - 環球醫療金融與技術咨詢服務有限公司（股份代號：2666）與中美腦中風協作組（SASG）共同主辦的「2015中國基層醫院腦卒中防治國際學術研討會暨第八屆中美心腦論壇」於10月19日至20日在河南鄭州市舉行。此次大會特別邀請了原衛生部副部長、中國老年保健協會、中國女醫師協會會長何界生、中國醫學科學院、北京協和醫學院公共衛生學院院長劉遠立、河南省衛計委有關領導，中美腦中風協作組專家、美國紐約北岸醫療集團專家組、國內知名醫院學科帶頭人、以及基層醫院的院長和相關科室醫生到場，接近500人參與是次盛會。此次會議旨在加強國內外學術交流，以解决基層醫院在推動卒中防治工程、臨床醫療技術發展等方面遇到的實際問題。原衛生部副部長、中國老年保健協會會長、中國女醫師協會會長何界生表示，「中國正在邁進老齡化進程，卒中的危害對我們的威脅正在日益放大，因此積極建立有效的卒中防治和治療管理體系是必要和至關重要的。」另外，北京協和醫學院公共衛生學院劉遠立院長指出，「中國是腦卒中的重災區。一方面，卒中具有發病率高、復發率高、致殘率高、死亡率高及經濟負擔高的5大突出特點，防控形式十分嚴峻；另一方面，中國在治療和管理卒中疾病的整體水準上還有待提高。」河南省衛計委領導指出，「河南是全國第一人口大省，腦卒中等慢性病患者眾多。這次腦卒中防治國際研討會在河南舉辦，對於加快河南省腦卒中防治體系建設、提升慢性病防治水準具有十分重要的借鑒意義。環球醫療和中美腦中風協作組在卒中防治理念傳播、技術培訓、設備引入、資金支援等方面開展了大量卓有成效的工作，幫助很多基層醫院建立起了安全、標準的心腦血管疾病防治中心，為眾多患者帶來了福音。」環球醫療金融與技術咨詢服務有限公司CEO郭衛平先生介紹，「從上世紀50年代開始，美國就對心腦血管疾病採取了許多防控措施。因此腦卒中發病率呈明顯下降趨勢，但在中國卻以比較快的速度上升。從資料上看，國內腦卒中患者的平均發病年齡為63歲，比美國的平均年齡73歲，早了10年。而且多學科聯合救治腦卒中患者在國外已經比較成熟和系統化。因此，我們環球醫療希望搭建一個學習和借鑒美國先進防控經驗的平台，快速地提高中國卒中的臨床和防控診療水準，這也與環球醫療正在積極開展國際、國內的醫療協作業務相吻合。」

與國際接軌 創建國家標準卒中中心 據國家衛計委腦卒中篩查與防治工程首席專家、中美腦卒中協作組中方組長張勤奕教授介紹，卒中中心建設將打破原有分科治療的壁壘，整合神經內外科、急救室、影像、介入科的力量，實現多學科協作的無縫對接，真正體現以患者為中心的服務理念。作為「2015中國基層醫院腦卒中防治國際學術研討會」的主辦方，環球醫療CEO郭衛平先生也介紹了公司舉辦這次峰會的初衷：「近年來國家出台一系列政策，設定了要基本實現大病不出縣，使縣域內就診率提高到90%左右的目標。而環球醫療作為中央企業的子公司，在推動國家腦卒中防治工程中理應率先擔當。從2011年起，我們與中美腦中風協作組合作，以「中國基層醫院卒中防治合作發展計劃」(SMILE計劃)方式，推動中國基層醫院腦卒中體系的建立。在20多個省幫助基層醫院在防控、篩查、規範治療、CEA手術等方面建立流程、培訓醫生、提升服務能力，並且已經在黑龍江齊齊哈爾、廣東茂名、山東日照等地推出了標杆醫院。2014年，全國CEA手術1778例，與我們合作的中美腦中風協作組專家就做了500多例，佔到全國手術量的近1/3。本次會議，我們也邀請到在神經內科和神經外科居世界領先地位的美國北岸醫院來介紹他們的前沿技術和管理經驗，從而幫助國內醫院提升神內神外學科的能力建設水準。」

環球醫療 提供全方位綜合醫療服務方案 近年中國醫療體制改革正在不斷深化，先後出台了社會資本辦醫、醫生多點執業等相關政策，並宣導通過政府與社會合作辦醫（PPP）的新模式推動醫療事業發展，推動公立醫院和社會資本的優勢相結合，這種改革已是大勢所趨。環球醫療CEO郭衛平先生表示，「這些都為環球醫療建立創新型一體化服務的模式提供了良好的商業契機和難得的發展機遇。作為中國最大的綜合醫療服務商，環球醫療為醫院客戶提供全方位綜合醫療服務解決方案，業務領域涵蓋醫療金融、醫院投資-建設-運營、醫療技術和醫療資訊化四大板塊。比如，像我們這樣的社會資本在與公立醫院的合作中，通過政府與社會合作辦醫（PPP）模式對公立醫院進行託管的方式，通過注入資金、建立機制、培養人員、優化流程等方面，著力優化醫療服務；且不增加居民醫療和財政負擔。」多年來，環球醫療致力於打造多元化的醫療資源平台，為醫院提供綜合醫療服務。目前，已經與國內30個省份的上千家醫院開展了廣泛的業務合作，與國內外數百名知名醫療專家建立了合作關係，並且與美國、歐洲的多家國際知名醫療服務機構建立了戰略合作夥伴關係。今年7月，環球醫療在香港聯合交易所主板正式掛牌上市。在未來的發展中，公將繼續以推動中國醫療服務產業發展為己任，不斷拓展醫療平台資源，奮實發展基礎，深化專業服務，創造持續增長的價值，將國外尖端先進技術和管理理念引入中國，培養一批醫德高尚、醫術精湛的醫學大師，為中國醫學發展做出貢獻。有關環球醫療金融與技術咨詢服務有限公司 環球醫療金融與技術咨詢服務有限公司（「環球醫療」或「公司」）是目前中國最大的綜合醫療服務供應商（按2014 年收入計，根據一家獨立諮詢公司報告）。公司專注於高速發展的中國醫療服務行業，以自身豐富的醫療資源平台為支撐，為醫院客戶提供一系列靈活多樣的綜合醫療解決方案。環球醫療的最大股東為中國通用技術（集團）控股有限責任公司，其是由中央直接管理的國有重要骨幹企業之一，也是《財富》世界500強企業。

有關中美腦中風協作組（SASG） 中美腦中風協作組通過培訓、教育和技術交流，透過有效的醫療技術手段，預防及治療腦卒中疾病，減少腦卒中疾病給社會帶來的危害，為卒中患者譜寫新的生命歷程。同時，向中國各級醫療機構提供醫療技術培訓服務。針對心腦血管疾病高危人群推廣以：健康教育、高危人群篩查、藥物治療、外科幹預為主的治療模式，支援各級醫院完善當地腦卒中篩查、治療技術。中美腦中風協作組擁有20餘家長期合作的夥伴，其中包括醫療機構、非營利的慈善組織及政府衛生部門、企業。目前，中美腦中風協作組得到大批熱心於中國腦卒中治療事業的醫生及工作人員的支援，至今已有來自中國、美國以及歐洲的50餘位國內外專家加入，並為其合作醫院提供醫療及技術支持。

有關中國基層醫院卒中防治合作發展計劃（Smile） 由環球醫療金融與技術諮詢服務有限公司與中美腦中風協作組共同發起，中美腦中風協作組（SASG）提供技術和管理理念，環球醫療提供設備和資金支援，集合世界上在防治中風領域的著名專家，對醫院的骨幹人員進行CEA手術、CAS介入、內科藥物治療、血管造影、影像、麻醉、重症監護等技術的培訓，旨在幫助全國基層醫院建立安全、標準的心腦血管病防治中心，進一步推廣和完善腦中風篩查及防控網路體系的建設。